The advancement of omics technology has vigorously promoted the development of the life sciences; metabolomics in particular has emerged as a powerful tool that has a promising future in scientific research and clinical practice. As terminal products of complex biochemical networks, endogenous low-molecular-weight metabolites contain rich information about the physiological status of an individual or group of people. Also, this information has more practical significance in that we know "what happened" instead of "what might happen" to some degree. Rapid and accurate screening of metabolites on a large scale was beyond imagining in the past; however, benefiting from high-throughput technical means, the overall disturbance of metabolites induced by environmental stimulus or treatments can now be well analyzed. After appropriate bioinformatic analysis, clinically relevant biomarkers of a disease can be found, and an accurate and dynamic picture of metabolic disturbance that contributes to a phenotype of a certain organism can be constructed. Biomarkers can also reveal the general metabolic condition by pathways that correlate with disease progression, or even with the risk of certain diseases. Thus, as an indispensable part of the framework of systems biology, metabolomics has been widely used in, but not limited to, the fields of medical science, pharmaceuticals, botany, and microbiology. In this article, we focus on metabolomics' mainstream research content and technical innovations such as determination methods for biologically active compounds; further, we pay more attention to the future trends and various possibilities for metabolomics study.
Keywords: Identification; mass spectrometry; metabolomics; principal component analysis.